Armed car-macrophage compositions and methods for therapy of hepatocellular carcinoma

TW202639173APending Publication Date: 2026-10-01RENABIO THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115101510
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-14
Filing Date
2026-01-14
Publication Date
2026-10-01

Smart Images

  • Figure TWG2TA001079045_001
    Figure TWG2TA001079045_001
  • Figure TWG2TA001079045_002
    Figure TWG2TA001079045_002
  • Figure TWG2TA001079045_003
    Figure TWG2TA001079045_003
Patent Text Reader

Abstract

A nanoparticle for treating hepatocellular carcinoma (HCC) in which the nanoparticle includes a lipid phase and a core that contains one or more nucleic acids encoding a chimeric antigen receptor (CAR), a T-cell engager (TCE), and / or a therapeutic gene. The CAR and the TCE each binding specifically to an HCC tumor-associated antigen and the nanoparticle selectively delivers the one or more nucleic acids to M2 macrophages in vitro or in vivo. Also provided is a therapeutic composition that contains a plurality of the nanoparticle described above and a pharmaceutically acceptable excipient. Further provided are methods for converting HCC tumor-resident M2 macrophages into M1 macrophages, and for treating HCC.
Need to check novelty before this filing date? Find Prior Art